News

News items

ESCD “best paper award” 2017/2

12 February, 2018

The ESCD “Best Paper Award” 2/2017 has been awarded for the contribution Allergic contact der matitis caused by isobornyl acrylate in Freestyle® Libre, a newly introduced glucose sensor” by Anne Herman and Olivier Aerts et al., Department of Dermatology, Cliniques Universitaires Saint-Luc, 1200, Brussels, Belgium, and Department of Dermatology, University Hospital Antwerp and University of Antwerp, 2650, Antwerp, Belgium, respectively, published in Contact Dermatitis 2017: 77: 367373 (see http://onlinelibrary.wiley.com/doi/10.1111/cod.12715/full).

Wolfgang Uter, 12 February 2018

Book review by Marie-Louise Schuttelaar – first monograph by Anton de Groot ‘non fragrance allergens in cosmetics’

19 January, 2018

Anton de Groot has published a new book – Monographs in Contact Allergy.  Volume I. is titled Non-fragrance allergens in cosmetics. This book is the first in a series of three. The second book will discuss fragrances and the third local and systemic drug reactions.

 

Here, Marie-Louise Schuttelaar reviews the first monograph:

Monographs in Contact Allergy, Volume I. Non-fragrance allergens in cosmetics

 

M.L.A. Schuttelaar, University Medical Center Groningen, Groningen, The Netherlands

 

This two-part 1430 pages book written by Anton de Groot presents 500 monographs on chemicals and substances that have caused contact allergy / allergic contact dermatitis by their presence in cosmetics. Each monograph begins with the section “Identification”: name, description/definition, chemical class, IUPAC name, other names, CIR and SCCS data, functions in cosmetics, patch testing advice, chemical formula and (beautifully drawn) structural formulas. In each monograph, data are provided (if such information is available) on results of patch testing in unselected patients suspected of contact dermatitis (routine testing), testing in selected patient groups (e.g., individuals suspected of cosmetic reactions, patients with leg ulcers, hairdressers, children, patients with periorbital dermatitis), case reports and case series of cosmetic allergy, allergy from non-cosmetic products, cross-reactivity, patch test sensitization, provocation tests, dilution series testing, chemical analyses and frequency of use in cosmetics in the USA (including recent data from FDA’s Voluntary Cosmetic Registration Program). Next, info is provided on irritant contact dermatitis, immediate contact reactions, non-eczematous adverse effects, systemic side effects and other relevant data. In other words, the monographs are not limited to cosmetic allergy but provide full reviews. Many are 1-3 pages only, but some monographs have >10 pages (e.g.,benzophenone-3, chlorhexidine digluconate, imidazolidinyl urea, propylene glycol), >20 (colophonium, formaldehyde, methylisothiazolinone) and even >30 pages (MCI/MI and p-phenylenediamine).

Because of our special interest in p-phenylenediamine, I have studied this monograph carefully and it proved to give a clear, informative, complete, very useful and detailed review of contact allergy and other side effects of p-phenylenediamine in hair dyes and other products with no less than 344 literature references. A nice touch was a bit of history about the French chemist Eugène Schueller, who marketed the product at the beginning of the 20th century with his French Harmless Hair Dye Company, from which L’Oreal developed. Knowing Anton, I am sure he has spent the same amount of energy and accuracy in all other monographs. Following the section with monographs (1325 pages) there are smaller chapters on immediate contact reactions, photosensitivity, a complete list of cosmetic functional groups (preservatives, sunscreens, humectants et cetera) and all chemicals in these groups that have caused cosmetic allergy, followed by a 30-page alphabetical list of synonyms referring to the names used for the monograph titles (INCI names where available).

After Patch Testing and Essential oils, this is yet another phenomenal reference book from Anton, which will make our work in the patch testing clinic easier and more fruitful and which is also very helpful for authors. I am looking out for the next two volumes in the Monographs series on Fragrances (volume II) and Topical and systemic drugs (Volume III).

 

Title: Monographs in Contact Allergy, Volume I. Non-fragrance allergens in cosmetics

Author: Anton C. de Groot

Edition: First Edition, 2018, 2 parts (ISBN 978-1-138-57325-3 and 978-1-138-57338-3)

Publisher: CRC Press Taylor & Francis group, Boca Raton, Fl, USA

Pages: 1430 +xxxvii

More info: https://www.crcpress.com/Monographs-in-Contact-Allergy-Volume-1-Non-Fragrance-Allergens-in-Cosmetics/Groot/p/book/9781138561137

Price: £190.00

 

 

 

 

ESCD 2018 Milan Congress website now live

19 January, 2018

The website for the 14th ESCD Congress to be held in Milan 18-20 October 2018 is now live. Please find details for registration and submission of abstracts
escd2018congress.com

The abstract submission date is set for April 2nd so please hurry !

Certain parts of the website, including the Registration button are not currently working. The ESCD has informed the Congress organiser and the PCO of these problems so they will hopefully be fixed quite soon.

Baseline Series Working Party request for feedback

20 December, 2017

The European Baseline Series working party recently met in Amsterdam and are seeking comments by the 28 February 2018 to suggested changes to the current European baseline series.

If you are logged in you can download the Word document below:

Sorry but this content is for subscribed members only. If you are an existing member, please renew your membership Or for new members please apply for membership.

If you’re already a member please login

 

Please send reasoned opinion to Mark Wilkinson  who is coordinating responses for the group.

 

Request for members comments on guidelines for Definition, Classification, Diagnosis and Management of Urticaria

26 October, 2017

The Executive Committee is keen to seek the opinion of ESCD members on the proposed EAACI/GALEN/EDF/WAO guidelines for the Definition, Classification, Diagnosis and Management of Urticaria (2017 Revision and Update)

View document: Proposed EAACI/GALEN/EDF/WAO guidelines for the Definition, Classification, Diagnosis and Management of Urticaria. (34 downloads)

The Society previously endorsed the 2013 guidelines. Please either email comments to secretary@escd.org

Closing date for comments Thursday 9 Nov 2017.

ESCD “best paper award” 2017/1

27 July, 2017

The ESCD “Best Paper Award” 1/2017 has been awarded for the contribution Rapid allergen-induced interleukin-17 and interferon-γ secretion by skin-resident memory CD8+ T cells” by Jonas D. Schmidt et al., Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvey 3, DK-2200 Copenhagen, published in Contact Dermatitis 2017: 76: 218-227 (see http://onlinelibrary.wiley.com/doi/10.1111/cod.12715/full).

Wolfgang Uter, 27 July 2017

ESCD “Best paper award” 2/2016

4 July, 2017

Following a suggestion from the Barcelona general assembly in 2014, and a subsequent agreement with Wiley publishers, the ESCD selects the best paper (among the many excellent contributions appearing … not always an easy choice!) per volume of the journal (Contact Dermatitis), following a standard operating procedure involving the ESCD Council.

Concerning volume 75 of Contact Dermatitis, the paper “Acetophenone azine: a new allergen responsible for severe contact dermatitis from shin pads”, Contact Dermatitis 2016: 75: 106-110 by Dr. Nadia Raison-Peyron, Department of Dermatology, Allergology Unit, Hôpital Saint Eloi – CHU Montpellier, 34295 Montpellier, France, and co-workers had been selected. Congratulations to this important work!

Wolfgang Uter, 4 July 2017

New working party “European Baseline Series” founded

4 July, 2017

On 13 June 2017, 18 ESCD members from 11 European countries met at the VU Amsterdam, very nicely hosted by Thomas Rustemeyer, for a constituting meeting of a new working party. This working party had been suggested and confirmed at the Manchester general assembly in September 2016; subsequently, a call for participation and the first meeting had been organised by the ESCD secretary, David Orton. In the apporox. 2 h of the initial meeting, a brainstorming of different conceptual aspects, but also of actual haptens to be included to, modified, or omitted from, the present European Baseline Series (EBS) were discussed. As an important organisational milestone, Mark Wilkinson, Leeds, UK (s.m.wilkinson@btinternet.com) was elected as working party convener and as vice convener Margarida Gonçalo, Coimbra, Portugal (mmgoncalo@gmail.com).

Preparatory work before the next meeting (11am on 28 November 2017, again at VU Amsterdam) will include refining criteria for inclusion in the EBS, suggesting modifications, also including a more experimental add-on series to the EBS, tested along with it in consecutive patients. The aim is to provide a definite change list for comments by the ESCD membership and ratification at the Milan meeting, 18 to 20 October 2018.

Wolfgang Uter, 4 July 2017

European activities on the harmonisation of authorisation of allergens

19 April, 2017

By Prof. V Mahler

In the EU, allergen products are defined as medicinal products according to Directive 2001/83/EC. This definition includes allergen products for the in vivo diagnosis of type IV hypersensitivities. However, despite the common legal framework set out by this directive, there is a considerable heterogeneity in the approach on how EU member states are actually regulating allergen products. The Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) was informed that the increased obligations related to the Pharmacovigilance legislation as well as GMP requirements, combined with limited reimbursement options in some EU Member States have led to a decreasing number of authorised allergens.

It was noted that different regulatory decisions are taken by Member States to allow allergen products on the market (marketed as named patient products vs. marketing authorisation per individual allergen or containing diverse active substances under one combined marketing authorisation). As a result of the regulatory disharmony observed in the EU and related problems thereof, the CMDh has created a drafting group that is now working on the development of proposals for harmonized regulatory approaches for allergen products within the EU.

Due to the complexity of the issues discussed in this group, it is expected that the activities will require some time to result in potential changes in the regulatory framework of allergen products. Current updates on the progress of the drafting group with respect to specific milestones will be referenced in the CMDh Meeting minutes which are publicly available at the CMDh website (http://www.hma.eu/457.html).

Furthermore, the CMDh has requested the Committee for Medicinal Products for Human Use (CHMP) to discuss the scientific requirements on allergens with lower prevalence. The CHMP agreed for a drafting group to work on a concept paper Minutes of the meeting from December 2016,